Meeting
2019 ASCO Annual Meeting
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).
Authors
Alona Zer
Sarcoma Unit, Davidoff Cancer Institute, Rabin Medical Center, affiliated to the Sackler Faculty of Medicine, Petach Tiqwa, Israel
Alona Zer , Oded Icht , Lilach Joseph , Dana Avram , Oded Jacobi , Eyal Fenig , Sivan Shamai , Ronnie Shapira Frommer , Hanna Bernstine , Rony Weitzen , Gil Bar-Sela , Salomon M. Stemmer , Michal Lotem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03219671
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11064)
DOI
10.1200/JCO.2019.37.15_suppl.11064
Abstract #
11064
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.
First Author: Vanessa Anne Eulo
Poster
2016 ASCO Annual Meeting
Modeling the cost of immune checkpoint inhibitor-related toxicities.
First Author: Neil Thomas Mason